Familial and inherited breast cancers in Lower Silesia (Poland)
The purpose of this study was to determine the frequencies of hereditary and familial breast cancers among Lower Silesian women. The questionnaires, dealing with cancer episodes in first-and second-degree relatives, were sent to 5,000 females, who were diagnosed with breast cancer between 1984 and 2005. Twenty-five percent of the questionnaires were completed and returned. Their analysis and further counseling revealed that 24.9% of the responders met the criteria for familial breast cancer (FBC), including 10.5% definitive cases. Mutations in BRCA1 were detected in 32.5% and 1.9% of patients with definitive and suspected FBC, respectively. They all represented three of the abnormalities of the BRCA1 gene: 300T/G, 4153delA and 5382insC. No mutations of BRCA2 were found in material studied. Although a fraction of FBCs identified in our study was similar to those described in other European countries and in the United States, the percentages of genetic mutations seen on routine tests were relatively low. Consequently, the standardized analysis of oncological pedigree seems to be a more valuable diagnostic tool if patients with familial aggregations of breast cancer are targeted in a prophylactic context only.
-  Y. Miki et al.: “A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1”, Science, Vol. 266, (1994), pp. 66–71.
-  R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, N. Collins, S. Gregory, C. Gumbs and G. Micklem: “Identification of the breast cancer susceptibility gene BRCA2”, Nature, Vol. 378, (1995), pp. 789–792. http://dx.doi.org/10.1038/378789a0[Crossref]
-  A.M. Martin and B.L. Weber: “Genetic and hormonal risk factors in breast cancer”, J. Natl. Cancer Inst., Vol. 92, (2000), pp. 1126–1135. http://dx.doi.org/10.1093/jnci/92.14.1126[Crossref]
-  S.W. Beenken and K.I. Bland: “Breast cancer genetics”, In: C.N. Ellis (Ed.): Inherited cancer syndromes. Current clinical management, Springer-Verlag, New York, Berlin, Heidelberg, 2004, pp. 91–133. http://dx.doi.org/10.1007/0-387-21596-4_5[Crossref]
-  R.W. Sattin, G.L. Rubin, L.A. Webster, C.M. Huezo, P.A. Wingo, H.W. Ory and P.M. Layde: “Family history and the risk of breast cancer”, JAMA, Vol. 253, (1985), pp. 1908–1913. http://dx.doi.org/10.1001/jama.253.13.1908[Crossref]
-  E.B. Claus, N.J. Risch and W.D. Thompson: “Age at onset as an indicator of familial risk of breast cancer”, Am. J. Epidemiol., Vol. 131, (1990), pp. 961–972.
-  G.A. Colditz, W.C. Willett, D.J. Hunter, M.J. Stampfer, J.E. Manson, C.H. Hennekens and B.A. Rosner: “Family history, age, and risk of breast cancer. Prospective data from the Nurses’ Health Study”, JAMA, Vol. 270, (1993), pp. 338–343. http://dx.doi.org/10.1001/jama.270.3.338[Crossref]
-  M.L. Slattery and R.A. Kerber: “A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database”, JAMA, Vol. 270, (1993), pp. 1563–1568. http://dx.doi.org/10.1001/jama.270.13.1563[Crossref]
-  K.A. Metcalfe, J.L. Semple and S.A. Narod: “Time to reconsider subcutaneous mastectomy for breast-cancer prevention?”, Lancet Oncol., Vol. 6, (2005), pp. 431–434. http://dx.doi.org/10.1016/S1470-2045(05)70210-2[Crossref]
-  R.T. Acton and L.M. Nabell: “Assessing genetic risk of cancer”, In: C.N. Ellis (Ed.): Inherited cancer syndromes. Current clinical management, Springer-Verlag, New York, Berlin, Heidelberg, 2004, pp. 1–29. http://dx.doi.org/10.1007/0-387-21596-4_1[Crossref]
-  J. Błaszczyk, M. Pudełko and K. Cisarż: Nowotwory złośliwe w województwie dolnośląskim w roku 2003, Dolnośląski Rejestr Nowotworów, Wrocław, 2005.
-  Ustawa z dnia 29 sierpnia 1997 r. o ochronie danych osobowych. Dz. U. 1997, nr 133, poz. 883.
-  D.K. Lahiri and J.I. NurnbergerJr: “A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies”, Nucleic Acids Res., Vol. 19, (1991), p. 5444. [Crossref]
-  L.S. Friedman, S.A. Gayther, T. Kurosaki, D. Gordon, B. Noble, G. Casey, P.A. Ponder and H. Anton-Culver: “Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population”, Am. J. Hum. Genet., Vol. 60, (1997), pp. 313–319.
-  F. Sanger, S. Nicklen and A.R. Coulson: “DNA sequencing with chain-terminating inhibitors”, Proc. Natl. Acad. Sci., Vol. 74, (1977), pp. 5463–5467. http://dx.doi.org/10.1073/pnas.74.12.5463[Crossref]
-  B. Górski et al.: “Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer”, Am. J. Hum. Genet., Vol. 66, (2000), pp. 1963–1968. http://dx.doi.org/10.1086/302922[Crossref]
-  B. Górski et al.: “A high proportion of founder BRCA1 mutations in Polish breast cancer families”, Int. J. Cancer, Vol. 110, (2004), pp. 683–686. http://dx.doi.org/10.1002/ijc.20162[Crossref]
-  M. van der Looij, B. Wysocka, I. Brożek, J. Jassem, J. Limon and E. Olah: “Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland”, Hum. Mutat., Vol. 15, (2000), pp. 480–481. http://dx.doi.org/10.1002/(SICI)1098-1004(200005)15:5<480::AID-HUMU13>3.0.CO;2-G[Crossref]
-  H. Janiszewska, O. Haus, A. Lauda-Świeciak, M. Pasińska, R. Laskowski, W. Szymański, B. Górski and J. Lubiński: “Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of Poland”, Clin. Genet., Vol. 64, (2003), pp. 502–508. http://dx.doi.org/10.1046/j.1399-0004.2003.00178.x[Crossref]
-  M. Perkowska, I. Brożek, B. Wysocka, K. Haraldsson, T. Sandberg, U. Johansson, G. Sellberg, A. Borg and J. Limon: “BRCA1 and BRCA2 mutation analysis in breastovarian cancer families from northeastern Poland”, Hum. Mutat., Vol. 21, (2003), pp. 553–554. http://dx.doi.org/10.1002/humu.9139[Crossref]
-  J. Steffen, D. Nowakowska, A. Niwińska, D. Czapczak, A. Kluska, M. Piątkowska, A. Wiśniewska and Z. Paszko: “Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland”, Int. J. Cancer, Vol. 119, (2006), pp. 472–475. http://dx.doi.org/10.1002/ijc.21853
-  J. Peto, N. Collins, R. Barfoot, S. Seal, W. Warren, N. Rahman, D.F. Easton, C. Evans, J. Deacon and M.R. Stratton: “Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer”, J. Natl. Cancer Inst., Vol. 91, (1999), pp. 943–949. http://dx.doi.org/10.1093/jnci/91.11.943[Crossref]
-  Anglian Breast Cancer Study Group: “Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases”, Br. J. Cancer, Vol. 83, (2000), pp. 1301–1308. http://dx.doi.org/10.1054/bjoc.2000.1407[Crossref]
-  D. Thompson and D. Easton: “The genetic epidemiology of breast cancer genes”, J. Mammary Gland Biol. Neoplasia, Vol. 9, (2004), pp. 221–236. http://dx.doi.org/10.1023/B:JOMG.0000048770.90334.3b[Crossref]
-  D.M. Eccles and G. Pichert: “Familial non-BRCA1/BRCA2-associated breast cancer”, Lancet Oncol., Vol. 6, (2005), pp. 705–711. [Crossref]
-  M.M. de Jong, I.M. Nolte, G.J. te Meerman, W.T. van der Graaf, J.C. Oosterwijk, J.H. Kleibeuker, M. Schaapveld and E.G. de Vries: “Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility”, J. Med. Genet., Vol. 39, (2002), pp. 225–242. http://dx.doi.org/10.1136/jmg.39.4.225[Crossref]
-  A.M. Dunning, M. Dowsett, C.S. Healey, L. Tee, R.N. Luben, E. Folkerd, K.L. Novik, L. Kelemen, S. Ogata, P.D. Pharoah, D.F. Easton, N.E. Day and B.A. Ponder: “Polymorphisms associated with circulating sex hormone levels in postmenopausal women”, J. Natl. Cancer Inst., Vol. 96, (2004), pp. 936–945. http://dx.doi.org/10.1093/jnci/djh167[Crossref]
-  R. Salovaara et al.: “Population-based molecular detection of hereditary nonpolyposis colorectal cancer”, J. Clin. Oncol., Vol. 18, (2000), pp. 2193–2200.
-  R. Braczkowski, E. Nowakowska-Zajdel, B. Zubelewicz, M. Muc-Wierzgon and W. Romanowski: “Genetic testing for breast cancer susceptibility: Polish women’s attitudes”, J. Exp. Clin. Cancer Res., Vol. 17, (1998), pp. 299–302.
-  K. Gwyn, S.W. Vernon and P.M. Conoley: “Intention to pursue genetic testing for breast cancer among women due for screening mammography”, Cancer Epidemiol. Biomarkers Prev., Vol. 12, (2003), pp. 96–102.